The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta-3-Adrenergic Receptor Agonists
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2018
At a glance
- Drugs Mirabegron (Primary)
- Indications Erectile dysfunction; Interstitial cystitis; Overactive bladder
- Focus Pharmacodynamics
- 15 Aug 2018 Planned primary completion date changed from 31 Jul 2018 to 31 Jul 2019.
- 26 Jun 2018 Preliminary data from healthy female volunteers (n=6) were presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 30 Dec 2017 Planned End Date changed from 31 Jul 2018 to 1 Oct 2021.